Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Northwestern University
- Study ID
- NCT06944353
- Status
- Enrolling By Invitation
Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Non-Alcoholic Fatty Liver Disease
- Steatosis of Liver
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- STIRRED — BEHAVIORALThe STIRRED intervention is a behavioral intervention directed at the treating ED clinicians. An Our Practice Advisory (OPA) will alert the clinician to the radiology finding of hepatic steatosis at the time of preparing the discharge materials. The OPA will prompt the clinician to discuss this finding with the patient and will automatically add hepatic steatosis to the discharge diagnoses and insert patient-facing discharge information about hepatic steatosis. It will additionally prompt the clinician to refer the patient for follow-up which will be stratified based on their fibrosis risk level.
Study Details
Hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. The investigators developed a clinical decision support system using machine learning and natural language processing that will prompt reporting to patients and provide ED clinicians risk stratified follow-up care recommendations. Data on both the implementation and effectiveness of our intervention resulting from this trial will inform future use with a goal of ultimately improving diagnostic safety and outcomes for patients with hepatic steatosis.
Key Dates
- Start date
- Dec 4, 2025
- Status verified
- May 2026
- Primary completion
- Jan 31, 2027
- Completion
- Jul 31, 2028
Study Design
- Enrollment
- 4,704 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- No Intervention: Usual CareIncludes any patient notification about steatosis, education and referrals as per the treating clinician's usual and customary practice.
- Experimental: STIRREDPatients with incidentally noted hepatic steatosis who are seen in Emergency Departments after STIRRED intervention has been activated within the local EHR may receive additional notification about steatosis, education or referrals for additional testing and follow-up as prompted by the STIRRED intervention which is directed at their discharging clinician.
Primary Outcome Measure
Effectiveness: New steatotic liver disease-related diagnosis among high-risk patients [ Time Frame: 120 days post-ED discharge ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | - |
Find similar trials in Chicago, IL
By research site
Related Studies
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseasePHASE2 · Not Yet Recruiting · Justin Ryder · Chicago, Illinois
- Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver DiseasePHASE2 · Recruiting · Justin Ryder · Chicago, Illinois
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- The Olmsted NAFLD Epidemiology Study (TONES)Recruiting · Mayo Clinic · Rochester, Minnesota